RESUMEN

Ribociclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is used in combination with an aromatase inhibitor in the first-line setting for advanced or metastatic hormone receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We report two cases of drug-induced vitiligo-like depigmentation (DI-VLD) associated with ribociclib. The awareness of this side effect is important given the increasing use of this drug and others with a similar mechanism of action.

Asunto(s)

Neoplasias de la Mama , Vitíligo , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/patología , Quinasa 4 Dependiente de la Ciclina , Femenino , Humanos , Inhibidores de Proteínas Quinasas/uso terapéutico , Vitíligo/inducido químicamente , Vitíligo/tratamiento farmacológico